Reset filter
Trefwoorden
D016430 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
    1. 7.1. Anesthesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynaecologie/Ostetrie
    1. 7.6. Interne geneeskunde
      1. Hematologie
      1. Epidemiologie
      1. Cardiologie/Angiologie
      1. Pneumologie
      1. Gastro-enterologie
      1. Nefrologie
      1. Endocrinologie/Metabolisme
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Oogheelkunde
    1. 7.9. Palliatieve zorg
    1. 7.10. Pathologie/Forensische Geneeskunde
    1. 7.11. Kindergeneeskunde
    1. 7.12. Psychiatrie/Psychosomatisch
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Algemene/maag-darm-chirurgie
      1. Neurochirurgie
      1. Plastische chirurgie
      1. Cardiothoracale chirurgie
      1. Traumachirurgie/Orthopedie
      1. Vaatchirurgie
    1. 7.15. Urologie
    1. 7.16. Tandheelkunde/MKG
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

657 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

MARS - Muenster Aging and Retina study Age-related macular degeneration - B. Eye diseases

- 20-09-21 - 17 Formulieren, 1 Itemgroep, 83 Data-elementen, 1 Taal
Itemgroep: Eye disease
Age-related macular degeneration (AMD) is a retinal degenerative disease that occurs at an advanced age and is the major cause of central visual acuity loss and old-age blindness in its final stages. The aim of the MARS study is to identify factors that influence the progression and course of age-related macular degeneration in a prospective study. To date, the following studies have been carried out on the MARS cohort: MARS-I: 2001-2003; MARS-II: 2004 - 2007; MARS-III: 2007-2009; MARS +: 2010/11. The study is provided by Prof. Dr. Hense, Institute of Epidemiology and Social medicine, University Clinic of Muenster.

Administrative documentation

1 Itemgroep 16 Data-elementen

A. Self-assessment of visual acuity

1 Itemgroep 9 Data-elementen

Interview

1 Itemgroep 5 Data-elementen

D. Slit lamp biomicroscopy I

1 Itemgroep 18 Data-elementen

H.Quality of Life

1 Itemgroep 24 Data-elementen

I. Family History

1 Itemgroep 21 Data-elementen

Acrylate Intraocular Lenses in Cataract Surgery of Uveitis Patients - Eligibility

- 03-06-17 - 1 Formulier, 2 Itemgroepen, 6 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00403832

LASER ADMINISTRATION FELLOW EYE (UNSCHEDULED) CRFs Roche FVF4170G Macular Edema NCT00473382

- 28-06-17 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Patient administration, LASER ADMINISTRATION STUDY EYE
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Study Eye Selection Screening Ranibizumab Macular Edema Secondary To Branch Retinal Vein Occlusion FVF4165g - Study Eye Selection Screening

- 18-03-18 - 1 Formulier, 1 Itemgroep, 7 Data-elementen, 1 Taal
Itemgroep: study eye
Study part: Study Eye Selection Screening. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects with Macular Edema Secondary To Branch Retinal Vein Occlusion.

Study Eye Selection Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4168g - Study Eye Selection Screening

- 20-03-18 - 1 Formulier, 1 Itemgroep, 6 Data-elementen, 1 Taal
Itemgroep: study eye
Study part: Study Eye Selection Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Study Eye Selection Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4170g - Study Eye Selection Screening

- 21-03-18 - 1 Formulier, 1 Itemgroep, 6 Data-elementen, 1 Taal
Itemgroep: study eye
Study part: Study Eye Selection Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

STUDY EYE SELECTION (SCREENING) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08-06-17 - 1 Formulier, 2 Itemgroepen, 6 Data-elementen, 1 Taal
Itemgroepen: Patient administration, Eligibility Criteria
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Vision Testing (Eye) Pazopanib Macular Degeneration MD1103367 - Vision Testing (Eye)

- 10-06-18 - 1 Formulier, 6 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: Subjective Refraction Right Eye, Subjective Refraction Left Eye, Visual Acuity, lntraocular Pressure, Slip Lamp Examination, Fundus Examination
Study part: Vision Testing (Eye). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

4 Meter Visual Acuity/ Left Eye Chart 2 Ranibizumab Macular Edema Secondary To Branch Retinal Vein Occlusion FVF4165g - 4 Meter Visual Acuity/ Left Eye Chart 2

- 18-03-18 - 1 Formulier, 4 Itemgroepen, 28 Data-elementen, 1 Taal
Itemgroepen: Visual acuity, Visual acuity, total score, Vision Tests
Study part: 4 Meter Visual Acuity/ Left Eye Chart 2. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects with Macular Edema Secondary To Branch Retinal Vein Occlusion.

4 Meter Visual Acuity/ Right Eye Chart 1 Ranibizumab Macular Edema Secondary To Branch Retinal Vein Occlusion FVF4165g - 4 Meter Visual Acuity/ Right Eye Chart 1

- 18-03-18 - 1 Formulier, 4 Itemgroepen, 28 Data-elementen, 1 Taal
Itemgroepen: Visual acuity, Visual acuity, total score, Vision Tests
Study part: 4 Meter Visual Acuity/ Right Eye Chart 1. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects with Macular Edema Secondary To Branch Retinal Vein Occlusion.

LASER ADMINISTRATION FELLOW EYE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

- 28-06-17 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Patient administration, LASER ADMINISTRATION STUDY EYE
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

LASER ADMINISTRATION STUDY EYE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

- 28-06-17 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Patient administration, LASER ADMINISTRATION STUDY EYE
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial